{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:45:13Z","timestamp":1790196313600,"version":"4.1.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-025-04132-y","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T09:15:43Z","timestamp":1742202943000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The influence of genetic factors on the clinical manifestations and response to systemic treatment of plaque psoriasis"],"prefix":"10.1007","volume":"317","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4120-6745","authenticated-orcid":false,"given":"Micha\u0142","family":"Majewski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6435-3863","authenticated-orcid":false,"given":"Piotr","family":"Konopelski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8308-1023","authenticated-orcid":false,"given":"Lidia","family":"Rudnicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,17]]},"reference":[{"key":"4132_CR1","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","volume":"370","author":"CE Griffiths","year":"2007","unstructured":"Griffiths CE, Barker JN (2007) Pathogenesis and clinical features of psoriasis. Lancet 370:263\u2013271","journal-title":"Lancet"},{"key":"4132_CR2","doi-asserted-by":"publisher","first-page":"511","DOI":"10.2478\/acph-2019-0047","volume":"69","author":"DL Drvar","year":"2019","unstructured":"Drvar DL, Vlahinic T, Males Z et al (2019) A modern approach to the treatment of plaque psoriasis. Acta Pharm 69:511\u2013523","journal-title":"Acta Pharm"},{"key":"4132_CR3","doi-asserted-by":"crossref","unstructured":"Langley RG, Krueger GG, Griffiths CE (2005) Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis; 64 Suppl 2: ii18-23; discussion ii4-5.","DOI":"10.1136\/ard.2004.033217"},{"key":"4132_CR4","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.clindermatol.2007.08.007","volume":"25","author":"JE Gudjonsson","year":"2007","unstructured":"Gudjonsson JE, Elder JT (2007) Psoriasis: epidemiology. Clin Dermatol 25:535\u2013546","journal-title":"Clin Dermatol"},{"key":"4132_CR5","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/ncprheum0987","volume":"5","author":"KE Nograles","year":"2009","unstructured":"Nograles KE, Brasington RD, Bowcock AM (2009) New insights into the pathogenesis and genetics of psoriatic arthritis. Nat Clin Pract Rheumatol 5:83\u201391","journal-title":"Nat Clin Pract Rheumatol"},{"issue":"Suppl 2","key":"4132_CR6","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/S0001-7310(09)73372-1","volume":"100","author":"RK Mak","year":"2009","unstructured":"Mak RK, Hundhausen C, Nestle FO (2009) Progress in Understanding the Immunopathogenesis of psoriasis. Actas Dermosifiliogr 100(Suppl 2):2\u201313","journal-title":"Actas Dermosifiliogr"},{"key":"4132_CR7","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S0190-9622(85)70188-0","volume":"13","author":"T Henseler","year":"1985","unstructured":"Henseler T, Christophers E (1985) Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 13:450\u2013456","journal-title":"J Am Acad Dermatol"},{"key":"4132_CR8","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s100670200097","volume":"21","author":"GM Alenius","year":"2002","unstructured":"Alenius GM, Jidell E, Nordmark L et al (2002) Disease manifestations and HLA antigens in psoriatic arthritis in Northern Sweden. Clin Rheumatol 21:357\u2013362","journal-title":"Clin Rheumatol"},{"key":"4132_CR9","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s40257-020-00585-1","volume":"22","author":"YW Huang","year":"2021","unstructured":"Huang YW, Tsai TF (2021) HLA-Cw1 and psoriasis. Am J Clin Dermatol 22:339\u2013347","journal-title":"Am J Clin Dermatol"},{"key":"4132_CR10","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/j.1365-4632.2004.02098.x","volume":"43","author":"X Zhang","year":"2004","unstructured":"Zhang X, Wei S, Yang S et al (2004) HLA-DQA1 and DQB1 alleles are associated with genetic susceptibility to psoriasis vulgaris in Chinese Han. Int J Dermatol 43:181\u2013187","journal-title":"Int J Dermatol"},{"key":"4132_CR11","doi-asserted-by":"publisher","first-page":"8","DOI":"10.2169\/internalmedicine.39.8","volume":"39","author":"S Shiozawa","year":"2000","unstructured":"Shiozawa S (2000) HLA-B39 and asymmetric arthritis. Intern Med 39:8\u20139","journal-title":"Intern Med"},{"key":"4132_CR12","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1002\/art.1780380619","volume":"38","author":"DD Gladman","year":"1995","unstructured":"Gladman DD, Farewell VT (1995) The role of HLA antigens as indicators of disease progression in psoriatic arthritis. Multivariate relative risk model. Arthritis Rheum 38:845\u2013850","journal-title":"Arthritis Rheum"},{"key":"4132_CR13","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1056\/NEJM197210122871503","volume":"287","author":"TJ Russell","year":"1972","unstructured":"Russell TJ, Schultes LM, Kuban DJ (1972) Histocompatibility (HL-A) antigens associated with psoriasis. N Engl J Med 287:738\u2013740","journal-title":"N Engl J Med"},{"key":"4132_CR14","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/rheumatology\/kev296","volume":"55","author":"R Queiro","year":"2016","unstructured":"Queiro R, Morante I, Cabezas I et al (2016) HLA-B27 and psoriatic disease: a modern view of an old relationship. Rheumatology (Oxford) 55:221\u2013229","journal-title":"Rheumatology (Oxford)"},{"key":"4132_CR15","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S0140-6736(74)91262-8","volume":"1","author":"DA Brewerton","year":"1974","unstructured":"Brewerton DA, Caffrey M, Nicholls A et al (1974) HL-A 27 and arthropathies associated with ulcerative colitis and psoriasis. Lancet 1:956\u2013958","journal-title":"Lancet"},{"key":"4132_CR16","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1111\/bjd.16083","volume":"178","author":"L Chen","year":"2018","unstructured":"Chen L, Tsai TF (2018) HLA-Cw6 and psoriasis. Br J Dermatol 178:854\u2013862","journal-title":"Br J Dermatol"},{"key":"4132_CR17","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1046\/j.0022-202x.2001.01656.x","volume":"118","author":"JE Gudjonsson","year":"2002","unstructured":"Gudjonsson JE, Karason A, Antonsdottir AA et al (2002) HLA-Cw6-positive and HLA-Cw6-negative patients with psoriasis vulgaris have distinct clinical features. J Invest Dermatol 118:362\u2013365","journal-title":"J Invest Dermatol"},{"key":"4132_CR18","unstructured":"Parameswaran P, Lucke M (2024) HLA-B27 Syndromes. In: StatPearls. Treasure Island (FL)"},{"key":"4132_CR19","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1136\/ard-2023-224434","volume":"82","author":"Z Li","year":"2023","unstructured":"Li Z, Khan MK, van der Linden SM et al (2023) HLA-B27, axial spondyloarthritis and survival. Ann Rheum Dis 82:1558\u20131567","journal-title":"Ann Rheum Dis"},{"key":"4132_CR20","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1136\/ard.2011.155044","volume":"71","author":"L Eder","year":"2012","unstructured":"Eder L, Chandran V, Pellet F et al (2012) Human leucocyte antigen risk alleles for psoriatic arthritis among patients with psoriasis. Ann Rheum Dis 71:50\u201355","journal-title":"Ann Rheum Dis"},{"key":"4132_CR21","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.humimm.2004.05.008","volume":"65","author":"W Luszczek","year":"2004","unstructured":"Luszczek W, Manczak M, Cislo M et al (2004) Gene for the activating natural killer cell receptor, KIR2DS1, is associated with susceptibility to psoriasis vulgaris. Hum Immunol 65:758\u2013766","journal-title":"Hum Immunol"},{"key":"4132_CR22","doi-asserted-by":"publisher","first-page":"e24927","DOI":"10.1371\/journal.pone.0024927","volume":"6","author":"CR Almeida","year":"2011","unstructured":"Almeida CR, Ashkenazi A, Shahaf G et al (2011) Human NK cells differ more in their KIR2DL1-dependent thresholds for HLA-Cw6-mediated Inhibition than in their maximal killing capacity. PLoS ONE 6:e24927","journal-title":"PLoS ONE"},{"key":"4132_CR23","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1111\/j.0022-202X.2004.22517.x","volume":"122","author":"Y Suzuki","year":"2004","unstructured":"Suzuki Y, Hamamoto Y, Ogasawara Y et al (2004) Genetic polymorphisms of killer cell immunoglobulin-like receptors are associated with susceptibility to psoriasis vulgaris. J Invest Dermatol 122:1133\u20131136","journal-title":"J Invest Dermatol"},{"key":"4132_CR24","doi-asserted-by":"publisher","first-page":"e12945","DOI":"10.1111\/sji.12945","volume":"92","author":"LL Ten Bergen","year":"2020","unstructured":"Ten Bergen LL, Petrovic A, Aarebrot AK et al (2020) Current knowledge on autoantigens and autoantibodies in psoriasis. Scand J Immunol 92:e12945","journal-title":"Scand J Immunol"},{"key":"4132_CR25","doi-asserted-by":"publisher","first-page":"e13096","DOI":"10.1111\/sji.13096","volume":"94","author":"H Sigurgrimsdottir","year":"2021","unstructured":"Sigurgrimsdottir H, Bjornsdottir EO, Eysteinsdottir JH et al (2021) Keratinocytes secrete multiple inflammatory and immune biomarkers, which are regulated by LL-37, in a psoriasis mimicking microenvironment. Scand J Immunol 94:e13096","journal-title":"Scand J Immunol"},{"key":"4132_CR26","doi-asserted-by":"crossref","unstructured":"Hwang YJ, Jung HJ, Kim MJ et al (2014) Serum levels of LL-37 and inflammatory cytokines in plaque and guttate psoriasis. Mediators Inflamm; 2014: 268257","DOI":"10.1155\/2014\/268257"},{"key":"4132_CR27","doi-asserted-by":"publisher","first-page":"5621","DOI":"10.1038\/ncomms6621","volume":"5","author":"R Lande","year":"2014","unstructured":"Lande R, Botti E, Jandus C et al (2014) The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nat Commun 5:5621","journal-title":"Nat Commun"},{"key":"4132_CR28","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jid.2016.09.035","volume":"137","author":"T Mabuchi","year":"2017","unstructured":"Mabuchi T, Hwang ST (2017) ACKR2: Nature\u2019s decoy receptor lures unsuspecting chemokines in psoriasis. J Invest Dermatol 137:7\u201311","journal-title":"J Invest Dermatol"},{"key":"4132_CR29","doi-asserted-by":"crossref","unstructured":"Pahar B, Madonna S, Das A et al (2020) Immunomodulatory role of the antimicrobial LL-37 peptide in autoimmune diseases and viral infections. Vaccines (Basel); 8","DOI":"10.3390\/vaccines8030517"},{"key":"4132_CR30","doi-asserted-by":"crossref","unstructured":"Takahashi T, Yamasaki K (2020) Psoriasis and antimicrobial peptides. Int J Mol Sci; 21","DOI":"10.3390\/ijms21186791"},{"key":"4132_CR31","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1111\/exd.13378","volume":"26","author":"J Fuentes-Duculan","year":"2017","unstructured":"Fuentes-Duculan J, Bonifacio KM, Hawkes JE et al (2017) Autoantigens ADAMTSL5 and LL37 are significantly upregulated in active psoriasis and localized with keratinocytes, dendritic cells and other leukocytes. Exp Dermatol 26:1075\u20131082","journal-title":"Exp Dermatol"},{"key":"4132_CR32","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.autrev.2011.01.011","volume":"10","author":"A Chatzikyriakidou","year":"2011","unstructured":"Chatzikyriakidou A, Voulgari PV, Drosos AA (2011) What is the role of HLA-B27 in spondyloarthropathies? Autoimmun Rev 10:464\u2013468","journal-title":"Autoimmun Rev"},{"key":"4132_CR33","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/art.22295","volume":"56","author":"MJ Turner","year":"2007","unstructured":"Turner MJ, Delay ML, Bai S et al (2007) HLA-B27 up-regulation causes accumulation of misfolded heavy chains and correlates with the magnitude of the unfolded protein response in Transgenic rats: implications for the pathogenesis of spondylarthritis-like disease. Arthritis Rheum 56:215\u2013223","journal-title":"Arthritis Rheum"},{"key":"4132_CR34","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1146\/annurev-immunol-032414-112110","volume":"33","author":"P Bowness","year":"2015","unstructured":"Bowness P (2015) Hla-B27. Annu Rev Immunol 33:29\u201348","journal-title":"Annu Rev Immunol"},{"key":"4132_CR35","doi-asserted-by":"publisher","first-page":"303","DOI":"10.5114\/reum.2022.120752","volume":"60","author":"W Owczarek","year":"2022","unstructured":"Owczarek W (2022) The role of HLA-Cw6 in psoriasis and psoriatic arthritis. Reumatologia 60:303\u2013305","journal-title":"Reumatologia"},{"key":"4132_CR36","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1016\/j.jaad.2022.07.050","volume":"87","author":"A Svedbom","year":"2022","unstructured":"Svedbom A, Stahle M (2022) Type 1 and type 2 psoriasis revisited: no association between age at onset and disease course. J Am Acad Dermatol 87:1438\u20131440","journal-title":"J Am Acad Dermatol"},{"key":"4132_CR37","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/sj.jid.5700118","volume":"126","author":"JE Gudjonsson","year":"2006","unstructured":"Gudjonsson JE, Karason A, Runarsdottir EH et al (2006) Distinct clinical differences between HLA-Cw*0602 positive and negative psoriasis patients\u2013an analysis of 1019 HLA-C- and HLA-B-typed patients. J Invest Dermatol 126:740\u2013745","journal-title":"J Invest Dermatol"},{"key":"4132_CR38","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2340\/00015555-0253","volume":"87","author":"X Fan","year":"2007","unstructured":"Fan X, Yang S, Sun LD et al (2007) Comparison of clinical features of HLA-Cw*0602-positive and -negative psoriasis patients in a Han Chinese population. Acta Derm Venereol 87:335\u2013340","journal-title":"Acta Derm Venereol"},{"key":"4132_CR39","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s00403-016-1618-y","volume":"308","author":"S Indhumathi","year":"2016","unstructured":"Indhumathi S, Rajappa M, Chandrashekar L et al (2016) The HLA-C*06 allele as a possible genetic predisposing factor to psoriasis in South Indian Tamils. Arch Dermatol Res 308:193\u2013199","journal-title":"Arch Dermatol Res"},{"key":"4132_CR40","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1093\/rheumatology\/41.5.525","volume":"41","author":"AM Al-Heresh","year":"2002","unstructured":"Al-Heresh AM, Proctor J, Jones SM et al (2002) Tumour necrosis factor-alpha polymorphism and the HLA-Cw*0602 allele in psoriatic arthritis. Rheumatology (Oxford) 41:525\u2013530","journal-title":"Rheumatology (Oxford)"},{"key":"4132_CR41","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/j.1744-313X.2005.00543.x","volume":"32","author":"A Szczerkowska Dobosz","year":"2005","unstructured":"Szczerkowska Dobosz A, Rebala K, Szczerkowska Z et al (2005) HLA-C locus alleles distribution in patients from Northern Poland with psoriatic arthritis\u2013preliminary report. Int J Immunogenet 32:389\u2013391","journal-title":"Int J Immunogenet"},{"key":"4132_CR42","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1093\/rheumatology\/ket363","volume":"53","author":"R Queiro","year":"2014","unstructured":"Queiro R, Tejon P, Alonso S et al (2014) Age at disease onset: a key factor for Understanding psoriatic disease. Rheumatology (Oxford) 53:1178\u20131185","journal-title":"Rheumatology (Oxford)"},{"key":"4132_CR43","first-page":"505","volume":"30","author":"R Queiro","year":"2003","unstructured":"Queiro R, Torre JC, Gonzalez S et al (2003) HLA antigens May influence the age of onset of psoriasis and psoriatic arthritis. J Rheumatol 30:505\u2013507","journal-title":"J Rheumatol"},{"key":"4132_CR44","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1136\/annrheumdis-2014-205461","volume":"75","author":"M Haroon","year":"2016","unstructured":"Haroon M, Winchester R, Giles JT et al (2016) Certain class I HLA alleles and haplotypes implicated in susceptibility play a role in determining specific features of the psoriatic arthritis phenotype. Ann Rheum Dis 75:155\u2013162","journal-title":"Ann Rheum Dis"},{"key":"4132_CR45","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.3899\/jrheum.151469","volume":"43","author":"L Eder","year":"2016","unstructured":"Eder L, Abji F, Rosen CF et al (2016) The association of HLA-class I genes and the extent of atherosclerotic plaques in patients with psoriatic disease. J Rheumatol 43:1844\u20131851","journal-title":"J Rheumatol"},{"key":"4132_CR46","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jdermsci.2008.04.016","volume":"52","author":"Y Jin","year":"2008","unstructured":"Jin Y, Zhang F, Yang S et al (2008) Combined effects of HLA-Cw6, body mass index and waist-hip ratio on psoriasis vulgaris in Chinese Han population. J Dermatol Sci 52:123\u2013129","journal-title":"J Dermatol Sci"},{"key":"4132_CR47","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1111\/ced.13100","volume":"42","author":"J West","year":"2017","unstructured":"West J, Ogston S, Berg J et al (2017) HLA-Cw6-positive patients with psoriasis show improved response to methotrexate treatment. Clin Exp Dermatol 42:651\u2013655","journal-title":"Clin Exp Dermatol"},{"key":"4132_CR48","doi-asserted-by":"publisher","first-page":"e611","DOI":"10.1111\/jdv.18870","volume":"37","author":"M Siewertsen","year":"2023","unstructured":"Siewertsen M, Al-Sofi R, Dridi H et al (2023) Association between HLA-Cw6 and response to treatment with biologics in patients with psoriasis: A systematic review and meta-analysis. J Eur Acad Dermatol Venereol 37:e611\u2013e4","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4132_CR49","doi-asserted-by":"crossref","unstructured":"Burlando M, Russo R, Clapasson A et al (2020) The HLA-Cw6 dilemma: is it really an outcome predictor in psoriasis patients under biologic therapy?? A monocentric retrospective analysis. J Clin Med; 9","DOI":"10.3390\/jcm9103140"},{"key":"4132_CR50","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1111\/bjd.13056","volume":"171","author":"HY Chiu","year":"2014","unstructured":"Chiu HY, Wang TS, Chan CC et al (2014) Human leucocyte antigen-Cw6 as a predictor for clinical response to Ustekinumab, an interleukin-12\/23 blocker, in Chinese patients with psoriasis: a retrospective analysis. Br J Dermatol 171:1181\u20131188","journal-title":"Br J Dermatol"},{"key":"4132_CR51","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1159\/000441719","volume":"232","author":"M Galluzzo","year":"2016","unstructured":"Galluzzo M, Boca AN, Botti E et al (2016) IL12B (p40) gene polymorphisms contribute to ustekinumab response prediction in psoriasis. Dermatology 232:230\u2013236","journal-title":"Dermatology"},{"key":"4132_CR52","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.jaad.2015.08.055","volume":"74","author":"M Talamonti","year":"2016","unstructured":"Talamonti M, Galluzzo M, Chimenti S et al (2016) HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: outcome and long-term follow-up. J Am Acad Dermatol 74:374\u2013375","journal-title":"J Am Acad Dermatol"},{"key":"4132_CR53","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1111\/bjd.16705","volume":"179","author":"A Costanzo","year":"2018","unstructured":"Costanzo A, Bianchi L, Flori ML et al (2018) Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study. Br J Dermatol 179:1072\u20131080","journal-title":"Br J Dermatol"},{"key":"4132_CR54","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s12016-012-8303-5","volume":"44","author":"V Chandran","year":"2013","unstructured":"Chandran V (2013) The genetics of psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol 44:149\u2013156","journal-title":"Clin Rev Allergy Immunol"},{"key":"4132_CR55","doi-asserted-by":"crossref","unstructured":"Rahman P, Elder JT (2005) Genetic epidemiology of psoriasis and psoriatic arthritis. Ann Rheum Dis; 64 Suppl 2: ii37-9; discussion ii40-1.","DOI":"10.1136\/ard.2004.030775"},{"key":"4132_CR56","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1136\/ard.61.9.857","volume":"61","author":"R Queiro","year":"2002","unstructured":"Queiro R, Sarasqueta C, Torre JC et al (2002) Spectrum of psoriatic spondyloarthropathy in a cohort of 100 Spanish patients. Ann Rheum Dis 61:857\u2013858","journal-title":"Ann Rheum Dis"},{"key":"4132_CR57","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1007\/s10067-016-3319-5","volume":"35","author":"TL Lai","year":"2016","unstructured":"Lai TL, Pang HT, Cheuk YY et al (2016) Psoriatic nail involvement and its relationship with distal interphalangeal joint disease. Clin Rheumatol 35:2031\u20132037","journal-title":"Clin Rheumatol"},{"key":"4132_CR58","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1590\/S0365-05962012000600004","volume":"87","author":"DG Ruiz","year":"2012","unstructured":"Ruiz DG, Azevedo MN, Lupi O (2012) HLA-B27 frequency in a group of patients with psoriatic arthritis. Bras Dermatol 87:847\u2013850","journal-title":"Bras Dermatol"},{"key":"4132_CR59","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1097\/ICU.0000000000000525","volume":"29","author":"G Jhaj","year":"2018","unstructured":"Jhaj G, Kopplin LJ (2018) Ocular features of the HLA-B27-positive seronegative spondyloarthropathies. Curr Opin Ophthalmol 29:552\u2013557","journal-title":"Curr Opin Ophthalmol"},{"key":"4132_CR60","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s40291-022-00603-4","volume":"26","author":"SS Ho","year":"2022","unstructured":"Ho SS, Tsai TF (2022) Associations between HLA-Cw1 and systemic treatment response of Asian psoriasis patients. Mol Diagn Ther 26:541\u2013549","journal-title":"Mol Diagn Ther"},{"key":"4132_CR61","doi-asserted-by":"publisher","first-page":"266","DOI":"10.31083\/j.fbl2709266","volume":"27","author":"X Zhou","year":"2022","unstructured":"Zhou X, He Y, Kuang Y et al (2022) HLA-DQA1 and DQB1 alleles are associated with acitretin response in patients with psoriasis. Front Biosci (Landmark Ed) 27:266","journal-title":"Front Biosci (Landmark Ed)"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-04132-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-025-04132-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-04132-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T09:25:15Z","timestamp":1742203515000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-025-04132-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,17]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4132"],"URL":"https:\/\/doi.org\/10.1007\/s00403-025-04132-y","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,17]]},"assertion":[{"value":"18 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Institutional review board approval was not required for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"582"}}